Protein S Deficiency

Protein S Deficiency is a topic covered in the 5-Minute Clinical Consult.

To view the entire topic, please or purchase a subscription.

Medicine Central™ is a quick-consult mobile and web resource that includes diagnosis, treatment, medications, and follow-up information on over 700 diseases and disorders, providing fast answers—anytime, anywhere. Explore these free sample topics:

Medicine Central

-- The first section of this topic is shown below --

Basics

Description

  • Protein S is a vitamin K–dependent glycoprotein, produced mainly in the liver that acts as a cofactor for protein C. It is also produced by megakaryocytes and endothelial cells.
  • Protein C becomes activated when thrombin binds to the endothelial receptor, thrombomodulin.
  • Activated protein C, with protein S (a cofactor), inactivates clotting factors Va and VIIIa enhancing fibrinolysis.
  • Protein S is also able to directly inhibit factors Va, VIIa, and Xa independently of activated protein C.
  • Protein S deficiency is a congenital thrombophilia, which increases the risk of thromboembolism.
  • It primarily affects the venous system.
  • System(s) affected: cardiovascular; hematologic/immunologic; pulmonary

Epidemiology

Incidence
  • Mean age of first thrombosis: 2nd decade
  • Predominant sex: male = female

Prevalence
  • ~0.2% of general population
  • Found in ~1% of persons with venous thrombosis embolism (VTE)

Etiology and Pathophysiology

  • It is an autosomal dominant disease.
  • Only the free form of protein S (30–40%) acts as a cofactor for activated protein C. Protein S reversibly binds to the C4b protein, which leads to conditions in which free protein S is low, but total protein S is normal. These individuals are prone to thrombosis.
  • Conditions with reduced protein S: pregnancy, oral contraceptives, warfarin, disseminated intravascular coagulation (DIC), liver disease, nephrotic syndrome, HIV, L-asparaginase chemotherapy, acute thrombosis, and acute varicella-zoster virus infection

Genetics
  • Is due to mutations in the PROS1 gene on chromosome 3. Most individuals are heterozygous.
  • Heterozygotes have an odds ratio (OR) of VTE of 1.6 to 11.5.
  • Homozygosity or compound heterozygosity, if untreated, is usually incompatible with adult life.
  • Homozygotes can have a fulminant thrombotic event in infancy, termed neonatal purpura fulminans.

Risk Factors

  • Oral contraceptives, pregnancy, and the use of HRT increase the risk of VTE in patients with protein S deficiency (1)[A].
  • Patients with protein S deficiency and other prothrombotic states have further increased rate of thrombosis (1)[A].
  • Arterial thrombosis is more frequent in patients with protein S deficiency who smoke.
  • Patients heterozygous for protein S deficiency who are initiated on warfarin without concomitant heparin can develop warfarin-induced skin necrosis because the half-life of other vitamin K–dependent clotting factors (e.g., prothrombin, factor IX, and factor X) is much longer than the anticoagulant protein S (4 to 8 hours), leading to a transient hypercoagulable state when protein S becomes depleted. These patients develop extremely low levels of protein S and develop necrosis of the skin over central areas of the body such as the breast, abdomen, buttocks, and genitalia (1)[A].

Pregnancy Considerations
Increased thrombotic risk and pregnancy losses

General Prevention

There are no preventive measures.

Commonly Associated Conditions

  • Deep and superficial VTE, often unprovoked
  • Up to 50% of homozygotes will have thrombosis.
  • Homozygosity is associated with catastrophic thrombotic complications at birth: neonatal purpura fulminans.
  • Sites of thrombosis can be unusual, including the mesentery, cerebral veins, and axillary veins.
  • Arterial thrombosis is rare but reported in several case reports.
  • Skin necrosis in patients treated with warfarin
  • Recurrent pregnancy losses (2)

-- To view the remaining sections of this topic, please or purchase a subscription --